

PRODUCT: ABT-263**ALTERNATE NAME:**


(R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-(4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-(trifluoromethyl)sulfonyl)phenyl)sulfonylbenzamide;
Navitoclax

CATALOG #:

2467-5, 25

AMOUNT:

5 mg, 25 mg

STRUCTURE:**MOLECULAR FORMULA:** $C_{45}H_{55}ClF_3N_5O_6S_3$ **MOLECULAR WEIGHT:**

974.61

CAS No.

923564-51-6

APPEARANCE:

White to off-white solid

SOLUBILITY:

DMSO (>50 mg/ml)

PURITY:

>98% by HPLC

STORAGE:

Store at -20°C. Protect from air and light

DESCRIPTION:

A potent, small molecule Bcl-2 family protein inhibitor (Ki's of <1 nmol/L for Bcl-2, Bcl-XL and Bcl-w). Displays anticancer properties. Selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w and prevents their binding to the apoptotic effectors Bax and Bak proteins, which may trigger apoptosis in tumor cells overexpressing Bcl-2, Bcl-XL, and Bcl-w.

REFERENCES:

Tse, C., *et al.* (2008). *Cancer Res.* **68**, 3421-3428.

HANDLING:

Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

ABT-737 (Cat. No. 2463-5, 25)

AT-101 (Cat. No. 2380-5, 25)

Bcl-2 Inhibitor, ABT-199 (Cat. No. 2253-1, 5)

Bcl-2 Inhibitor, GX15-070 (Cat. No. 2040-5)

FOR RESEARCH USE ONLY! Not to be used in humans.